Aliskiren is an orally active, nonpeptide, potent direct renin inhibitor that decreases plasma renin activity (PRA) and inhibits the conversion of angiotensinogen to angiotensin I. Unlike ACE ...
Morning Overview on MSN
Study flags new blood-pressure switch, pointing to fresh treatments
Nearly half of all adults in the United States have high blood pressure, and the drugs used to treat it, while effective, ...
Vienna, Austria - The addition of aliskiren (Tekturna, Novartis) to the standard pharmacologic assault on the renin-angiotensin system (RAS) in chronic heart failure earned a vote of confidence from a ...
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
It's long been known that use of a renin-angiotensin-aldosterone system (RAAS) antagonist slows the progression of kidney disease and specifically slows progression of advanced kidney disease, ...
Aliskiren 150 mg, hydrochlorothiazide (HCTZ) 12.5 mg; tabs. Tekturna HCT combines the antihypertensive drugs aliskiren, a direct renin inhibitor, and the thiazide diuretic, hydrochlorothiazide (HCTZ).
For patients with advanced and progressive chronic kidney disease, discontinuation of treatment with renin-angiotensin system (RAS) inhibitors is not associated with a difference in the long-term rate ...
SGLT2i and GLP-1RA are associated with lower risks of hyperkalemia compared with DPP4i in patients with CKD and type 2 diabetes. Hyperkalemia risks in patients with chronic kidney disease (CKD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results